Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
September 5, 2007

SymBio Obtains Rights to Leukemia Drug Candidate

  • SymBio Pharmaceuticals obtained rights to a drug that’s touted to have therapeutic potential to treat Gleevec-resistant chronic myeloid leukemia and mast cell leukemia.

    PEG-ZnPP was developed by Hiroshi Maeda and fellow researchers at Sojo University. According to Maeda, PEG-ZnPP exhibits an inhibitory antitumor effect on heme oxygenase activity, leading to an increase in the production of toxic oxidants and eventual cancer cell death.

    This exclusive global license adds a third clinical candidation to SymBio’s pipeline.

  • You’re all set! Thank you for subscribing to GEN Highlights.